HESPERIDIN

OTHER NAME(S):

Bioflavonoid, Bioflavonoid Complex, Bioflavonoid Concentrate, Bioflavonoid Extract, Bioflavonoïde, Bioflavonoïde d'Agrume, Bioflavonoïdes d'Agrumes, Citrus Bioflavones, Citrus Bioflavonoid, Citrus Bioflavonoids, Citrus Bioflavonoid Extract, Citrus Flavones, Citrus Flavonoids, Complexe de Bioflavonoïdes, Concentré de Bioflavonoïdes, Extrait de Bioflavonoïdes, Extrait de Bioflavonoïdes d'Agrumes, Flavonoid, Flavonoïde, Hesperidin Methyl Chalcone, Hesperidina, Hespéridine, Trimethylhesperidin-chalcon.<br/><br/>

Overview

Overview Information

Hesperidin is a plant chemical that is classified as a "bioflavonoid." It is found primarily in citrus fruits. People use it as medicine.

Hesperidin alone, or in combination with other citrus bioflavonoids (diosmin, for example), is most commonly used for blood vessel conditions such as hemorrhoids, varicose veins, and poor circulation (venous stasis).

How does it work?

Hesperidin may help blood vessels function better. It may also reduce inflammation.

Uses

Uses & Effectiveness?

Possibly Effective for

  • Poor circulation in the legs (chronic venous insufficiency, CVI). Taking a particular product containing hesperidin methyl chalcone, butcher's broom, and vitamin C by mouth seems to relieve the symptoms of poor circulation in the legs. Also, taking a different product containing hesperidin and diosmin by mouth for 2-6 months seems to improve CVI symptoms, although taking the drug Venoruton might be more effective for treating this condition.
  • Hemorrhoids. Some research suggests that taking hesperidin and diosmin improves symptoms of anal hemorrhoids. It may also prevent hemorrhoids from coming back after they have healed and may help in an emergency worsening of hemorrhoids.
  • Leg ulcers from poor circulation (venous stasis ulcers). Taking a specific product containing hesperidin and diosmin by mouth for 2 months seems to improve the healing of small venous stasis ulcers when used along with compression dressings.

Possibly Ineffective for

  • High cholesterol. Some research shows that taking hesperidin does not affect cholesterol.
  • Weight loss. Some research shows that taking glucosyl hesperidin for 12 weeks does not reduce body weight in people that are modestly overweight.

Insufficient Evidence for

  • Diabetes. Early research suggests that taking one tablet of a specific product containing hesperidin and diosmin by mouth for 45 days decreases blood sugar levels and improves blood sugar control in women with type 2 diabetes.
  • High blood pressure. Early research suggests that taking hesperidin by mouth or drinking orange juice containing hesperidin can decrease diastolic blood pressure (the bottom number) but does not decrease systolic blood pressure (the top number) in people with or without high blood pressure.
  • Swelling of the arms (lymphedema). Early research suggests that taking a specific product containing butcher's broom root extract, hesperidin methyl chalcone, and vitamin C by mouth for 90 days reduces swelling in the upper arm and forearm and improves mobility and heaviness in women with swelling of the arm after breast cancer treatment. However, other research shows that taking a different product containing hesperidin and diosmin by mouth does not reduce arm swelling in women following breast cancer surgery.
  • Rheumatoid arthritis (RA). Early research suggests that drinking a beverage containing alpha-glucosyl hesperidin for 12 weeks improves symptoms of RA.
  • Varicose veins.
  • Other conditions.
More evidence is needed to rate the effectiveness of hesperidin for these uses.

Side Effects

Side Effects & Safety

Hesperidin is POSSIBLY SAFE for most people when taken by mouth for up to 6 months. The safety of using it for a longer period of time is unknown. Side effects include stomach pain and upset, diarrhea, and headache.

Special Precautions & Warnings:

Pregnancy and breast-feeding: Hesperidin is POSSIBLY SAFE for pregnant or breast-feeding women when taken by mouth with diosmin.

Bleeding disorder: Hesperidin might slow blood clotting and increase the risk of bleeding. In theory, hesperidin might make bleeding disorders worse.

Low blood pressure: Hesperidin might lower blood pressure. In theory, taking hesperidin might make blood pressure become too low in people who already have low blood pressure.

Surgery: Hesperidin might prolong bleeding. There is concern that hesperidin might increase the risk of bleeding during and after surgical procedures. Stop taking hesperidin at least 2 weeks before a scheduled surgery.

Interactions

Interactions?

We currently have no information for HESPERIDIN Interactions.

Dosing

Dosing

The following doses have been studied in scientific research:

ADULTS

BY MOUTH:

  • For poor circulation in the legs (chronic venous insufficiency): A specific combination product containing hesperidin methyl chalcone 150 mg, butcher's broom root extract 150 mg, and ascorbic acid 100 mg has been used. Also, a combination of 100-150 mg of hesperidin with 900-1350 mg of diosmin taken daily for 2-6 months has been used.
  • For hemorrhoids: a combination of 150 mg of hesperidin plus 1350 mg of diosmin twice daily for 4 days, followed by 100 mg of hesperidin and 900 mg of diosmin twice daily for 3 days has been used. Also, a combination of 50 mg of hesperidin plus 450 mg of diosmin twice daily for 3 months has been used to prevent the return of hemorrhoids.
  • For leg ulcers caused by poor blood circulation (venous stasis ulcers): a combination of 100 mg of hesperidin and 900 mg of diosmin daily for up to 2 months has been used.

View References

REFERENCES:

  • Akiyama, S., Katsumata, S., Suzuki, K., Nakaya, Y., Ishimi, Y., and Uehara, M. Hypoglycemic and hypolipidemic effects of hesperidin and cyclodextrin-clathrated hesperetin in Goto-Kakizaki rats with type 2 diabetes. Biosci.Biotechnol.Biochem. 2009;73(12):2779-2782. View abstract.
  • Aliev, S. A., Ibishov, K. G., and Aliev, E. S. [Certain aspects of pathogenesis of hemorheological and trophic disturbances and their pharmacological correction in patients with chronic venous insufficiency]. Vestn.Khir.Im I.I.Grek. 2008;167(2):39-43. View abstract.
  • Allegra, C., Bartolo, M., Jr., Carioti, B., and Cassiani, D. An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency. Int J Microcirc.Clin Exp 1995;15 Suppl 1:50-54. View abstract.
  • Amato, C. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin. Angiology 1994;45(6 Pt 2):531-536. View abstract.
  • Ameer, B., Weintraub, R. A., Johnson, J. V., Yost, R. A., and Rouseff, R. L. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther 1996;60(1):34-40. View abstract.
  • Amiel, M. and Barbe, R. [Study of the pharmacodynamic activity of daflon 500 mg]. Ann.Cardiol.Angeiol.(Paris) 1998;47(3):185-188. View abstract.
  • Belcaro, G., Cesarone, M. R., de Sanctis, M. T., Incandela, L., Laurora, G., Fevrier, B., Wargon, C., and De, Gregoris P. Laser Doppler and transcutaneous oximetry: modern investigations to assess drug efficacy in chronic venous insufficiency. Int.J.Microcirc.Clin.Exp. 1995;15 Suppl 1:45-49. View abstract.
  • Beltramino, R., Penenory, A., and Buceta, A. M. An open-label, randomised multicentre study comparing the efficacy and safety of CYCLO 3 FORT versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Int Angiol. 1999;18(4):337-342. View abstract.
  • Bergan, J. J., Schmid-Schonbein, G. W., and Takase, S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. Angiology 2001;52 Suppl 1:S43-S47. View abstract.
  • BOOTH, A. N., JONES, F. T., and DeEDS, F. Metabolic fate of hesperidin, eriodictyol, homoeridictyol, and diosmin. J.Biol.Chem. 1958;230(2):661-668. View abstract.
  • Bouaziz, N., Michiels, C., Janssens, D., Berna, N., Eliaers, F., Panconi, E., and Remacle, J. Effect of Ruscus extract and hesperidin methylchalcone on hypoxia-induced activation of endothelial cells. Int Angiol. 1999;18(4):306-312. View abstract.
  • Bouskela, E. and Donyo, K. A. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch. Angiology 1997;48(5):391-399. View abstract.
  • Boyle, P., Diehm, C., and Robertson, C. Meta-analysis of clinical trials of Cyclo 3 Fort in the treatment of chronic venous insufficiency. Int Angiol. 2003;22(3):250-262. View abstract.
  • Brett, G. M., Hollands, W., Needs, P. W., Teucher, B., Dainty, J. R., Davis, B. D., Brodbelt, J. S., and Kroon, P. A. Absorption, metabolism and excretion of flavanones from single portions of orange fruit and juice and effects of anthropometric variables and contraceptive pill use on flavanone excretion. Br.J.Nutr. 2009;101(5):664-675. View abstract.
  • Buckshee, K., Takkar, D., and Aggarwal, N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy. Int J Gynaecol Obstet 1997;57(2):145-151. View abstract.
  • Cesarone, M. R., Belcaro, G., Pellegrini, L., Ledda, A., Di Renzo, A., Vinciguerra, G., Ricci, A., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Acerbi, G., and Cacchio, M. HR, 0-(beta-hydroxyethyl)-rutosides, in comparison with diosmin+hesperidin in chronic venous insufficiency and venous microangiopathy: an independent, prospective, comparative registry study. Angiology 2005;56(1):1-8. View abstract.
  • Cesarone, M. R., Belcaro, G., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Di Renzo, A., Ruffini, I., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Acerbi, G., Cornelli, U., Hosoi, M., and Cacchio, M. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency. Angiology 2006;57(2):131-138. View abstract.
  • Cesarone, M. R., Belcaro, G., Rohdewald, P., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Acerbi, G., Cacchio, M., Di Renzo, A., Hosoi, M., Stuard, S., and Corsi, M. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb.Hemost. 2006;12(2):205-212. View abstract.
  • Chassignolle, J. F., Amiel, M., Lanfranchi, G., and et al. Activité thérapeutique de Daflon 500 mg dans l'insuffisance veineuse fonctionnelle [in French]. J Int Med 1987;99:32-37.
  • Chiba, H., Uehara, M., Wu, J., Wang, X., Masuyama, R., Suzuki, K., Kanazawa, K., and Ishimi, Y. Hesperidin, a citrus flavonoid, inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice. J.Nutr. 2003;133(6):1892-1897. View abstract.
  • Cluzan, R. V., Alliot, F., Ghabboun, S., and Pascot, M. Treatment of secondary lymphedema of the upper limb with CYCLO 3 FORT. Lymphology 1996;29(1):29-35. View abstract.
  • Cospite, M. and Dominici, A. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form. Int Angiol. 1989;8(4 Suppl):61-65. View abstract.
  • Cospite, M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Drugs Today 1995;31(Suppl E):49-55.
  • Cypriani, B., Limasset, B., Carrie, M. L., le Doucen, C., Roussie, M., de Paulet, A. C., and Damon, M. Antioxidant activity of micronized diosmin on oxygen species from stimulated human neutrophils. Biochem Pharmacol 4-6-1993;45(7):1531-1535. View abstract.
  • El-Readi, M. Z., Hamdan, D., Farrag, N., El-Shazly, A., and Wink, M. Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines. Eur.J.Pharmacol. 1-25-2010;626(2-3):139-145. View abstract.
  • Fenton, J. I. and Hord, N. G. Flavonoids promote cell migration in nontumorigenic colon epithelial cells differing in Apc genotype: implications of matrix metalloproteinase activity. Nutr.Cancer 2004;48(2):182-188. View abstract.
  • Fernandez, S. P., Wasowski, C., Paladini, A. C., and Marder, M. Synergistic interaction between hesperidin, a natural flavonoid, and diazepam. Eur.J.Pharmacol. 4-11-2005;512(2-3):189-198. View abstract.
  • Galley, P. and Thiollet, M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol. 1993;12(1):69-72. View abstract.
  • Gardana, C., Guarnieri, S., Riso, P., Simonetti, P., and Porrini, M. Flavanone plasma pharmacokinetics from blood orange juice in human subjects. Br.J.Nutr. 2007;98(1):165-172. View abstract.
  • Geroulakos, G. and Nicolaides, A. N. Controlled studies of Daflon 500 mg in chronic venous insufficiency. Angiology 1994;45(6 Pt 2):549-553. View abstract.
  • Gilly, R., Pillion, G., and Frileux, C. Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology. 1994;9(2):67-70.
  • Glinski, W, Chodynicka, B., Roszkiewicz, J., and et al. The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicentre, controlled, randomised study. Phlebology. 1999;14(4):151-157.
  • Godeberge, P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology 1994;45(6 Pt 2):574-578. View abstract.
  • Guex, J. J., Enrici, E., Boussetta, S., Avril, L., Lis, C., and Taieb, C. Correlations between ankle circumference, symptoms, and quality of life demonstrate the clinical relevance of minimal leg swelling reduction: results of a study in 1,036 Argentinean patients. Dermatol.Surg. 2008;34(12):1666-1675. View abstract.
  • Guilhou, J. J., Fevrier, F., Debure, C., Dubeaux, D., Gillet-Terver, M. N., Guillot, B., Levesque, H., Marzin, L., Mignot, J., Ouvry, P., Pillion, G., Van, Landuyt H., Zuccarelli, F., and Nicolaides, A. N. Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double-blind, controlled versus placebo trial. Int.J.Microcirc.Clin.Exp. 1997;17 Suppl 1:21-26. View abstract.
  • Guillot, B. Techniques used to evaluate the cutaneous microcirculation: application of photoplethysmography to the assessment of a phlebotropic agent in the treatment of leg ulcers. Angiology 1994;45(6 Pt 2):542-548. View abstract.
  • Ho, Y. H., Foo, C. L., Seow-Choen, F., and Goh, H. S. Prospective randomized controlled trial of a micronized flavonidic fraction to reduce bleeding after haemorrhoidectomy. Br J Surg. 1995;82(8):1034-1035. View abstract.
  • Hosseinimehr, S. J., Ahmadi, A., Beiki, D., Habibi, E., and Mahmoudzadeh, A. Protective effects of hesperidin against genotoxicity induced by (99m)Tc-MIBI in human cultured lymphocyte cells. Nucl.Med.Biol. 2009;36(7):863-867. View abstract.
  • Hwang, S. L. and Yen, G. C. Neuroprotective effects of the citrus flavanones against H2O2-induced cytotoxicity in PC12 cells. J.Agric.Food Chem. 2-13-2008;56(3):859-864. View abstract.
  • Ibegbuna, V., Nicolaides, A. N., Sowade, O., Leon, M., and Geroulakos, G. Venous elasticity after treatment with Daflon 500 mg. Angiology 1997;48(1):45-49. View abstract.
  • Iqbal, M. F. and Zhu, W. Y. Bioactivation of flavonoid diglycosides by chicken cecal bacteria. FEMS Microbiol.Lett. 2009;295(1):30-41. View abstract.
  • Jantet, G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology 2002;53(3):245-256. View abstract.
  • Jean, T. and Bodinier, M. C. Mediators involved in inflammation: effects of Daflon 500 mg on their release. Angiology 1994;45(6 Pt 2):554-559. View abstract.
  • Jin, Y. R., Han, X. H., Zhang, Y. H., Lee, J. J., Lim, Y., Chung, J. H., and Yun, Y. P. Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-gamma2 phosphorylation and cyclooxygenase-1 activity. Atherosclerosis 2007;194(1):144-152. View abstract.
  • Jung, U. J., Lee, M. K., Jeong, K. S., and Choi, M. S. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J.Nutr. 2004;134(10):2499-2503. View abstract.
  • Juteau, N., Bakri, F., Pomies, J. P., Foulon, C., Rigaudy, P., Pillion, G., Lange, G., Genre, O., and Cron, J. P. The human saphenous vein in pharmacology: effect of a new micronized flavonoidic fraction (Daflon 500 mg) on norepinephrine induced contraction. Int Angiol. 1995;14(3 Suppl 1):8-13. View abstract.
  • Kanaze, F. I., Bounartzi, M. I., Georgarakis, M., and Niopas, I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur.J.Clin.Nutr. 2007;61(4):472-477. View abstract.
  • Keenoy, B., Vertommen, J., and De, Leeuw, I. The effect of flavonoid treatment on the glycation and antioxidant status in Type 1 diabetic patients. Diabetes Nutr Metab 1999;12(4):256-263. View abstract.
  • Kim, D. H., Jung, E. A., Sohng, I. S., Han, J. A., Kim, T. H., and Han, M. J. Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch Pharm.Res. 1998;21(1):17-23. View abstract.
  • Kim, J. Y., Jung, K. J., Choi, J. S., and Chung, H. Y. Modulation of the age-related nuclear factor-kappaB (NF-kappaB) pathway by hesperetin. Aging Cell 2006;5(5):401-411. View abstract.
  • Kometani, T., Fukuda, T., Kakuma, T., Kawaguchi, K., Tamura, W., Kumazawa, Y., and Nagata, K. Effects of alpha-glucosylhesperidin, a bioactive food material, on collagen-induced arthritis in mice and rheumatoid arthritis in humans. Immunopharmacol.Immunotoxicol. 2008;30(1):117-134. View abstract.
  • Korthuis, R. J. and Gute, D. C. Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micronized purified flavonoid fraction. J Vasc.Res 1999;36 Suppl 1:15-23. View abstract.
  • Kumar, P. and Kumar, A. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide. Behav.Brain Res. 1-5-2010;206(1):38-46. View abstract.
  • La Torre, F., Nicolai, A. P., and Otti, M. [Hemorrhoids and conservative treatment. Review of the literature on the use of diosmin and micronized hesperidin]. Minerva Chir 1999;54(12):909-916. View abstract.
  • Launois, R. At the crossroads of venous insufficiency and hemorrhoidal disease: Daflon 500 mg--repercussions of venous insufficiency on everyday life. Angiology 1994;45(6 Pt 2):495-504. View abstract.
  • Li, Y. M., Li, X. M., Li, G. M., Du, W. C., Zhang, J., Li, W. X., Xu, J., Hu, M., and Zhu, Z. In vivo pharmacokinetics of hesperidin are affected by treatment with glucosidase-like BglA protein isolated from yeasts. J.Agric.Food Chem. 7-23-2008;56(14):5550-5557. View abstract.
  • Loscalzo, L. M., Wasowski, C., Paladini, A. C., and Marder, M. Opioid receptors are involved in the sedative and antinociceptive effects of hesperidin as well as in its potentiation with benzodiazepines. Eur.J.Pharmacol. 2-12-2008;580(3):306-313. View abstract.
  • Lyseng-Williamson, K. A. and Perry, C. M. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 2003;63(1):71-100. View abstract.
  • Menyhei, G., Acsady, G., Hetenyi, A., and et al. Chronobiology and clinical activity of Daflon 500 mg in chronic venous insufficiency. Phlebology. 1994;9(1):53-59.
  • Meyer, O. C. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology 1994;45(6 Pt 2):579-584. View abstract.
  • Mlakar, B. and Kosorok, P. Flavonoids to reduce bleeding and pain after stapled hemorrhoidopexy: a randomized controlled trial. Wien.Klin.Wochenschr. 2005;117(15-16):558-560. View abstract.
  • Pokrovsky, A. V., Saveljev, V. S., Kirienko, A. I., Bogachev, V. Y., Zolotukhin, I. A., Sapelkin, S. V., Shvalb, P. G., Zhukov, B. N., Vozlubleny, S. I., Sabelnikov, V. V., Voskanian, Y. E., Katelnitsky, I. I., Burleva, E. P., and Tolstikhin, V. Y. Surgical correction of varicose vein disease under micronized diosmin protection (results of the Russian multicenter controlled trial DEFANS). Angiol.Sosud.Khir. 2007;13(2):47-55. View abstract.
  • Ramelet, A. A. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. Angiology 2001;52 Suppl 1:S49-S56. View abstract.
  • Roumy, J., Herault, S., Tobal, N., Besnard, S., and Arbeille, P. Effect of a venotonic agent on the main arteries and veins during a 5 day HDT. Acta Astronaut. 2001;49(3-10):161-166. View abstract.
  • Rudofsky, G. [Improving venous tone and capillary sealing. Effect of a combination of Ruscus extract and hesperidine methyl chalcone in healthy probands in heat stress]. Fortschr.Med 6-30-1989;107(19):52, 55-52, 58. View abstract.
  • Saha, R. K., Takahashi, T., and Suzuki, T. Glucosyl hesperidin prevents influenza a virus replication in vitro by inhibition of viral sialidase. Biol.Pharm.Bull. 2009;32(7):1188-1192. View abstract.
  • Sakata, K., Hirose, Y., Qiao, Z., Tanaka, T., and Mori, H. Inhibition of inducible isoforms of cyclooxygenase and nitric oxide synthase by flavonoid hesperidin in mouse macrophage cell line. Cancer Lett. 9-25-2003;199(2):139-145. View abstract.
  • Smith, P. D. Neutrophil activation and mediators of inflammation in chronic venous insufficiency. J Vasc.Res 1999;36 Suppl 1:24-36. View abstract.
  • Struckmann, J. R. and Nicolaides, A. N. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders. Angiology 1994;45(6):419-428. View abstract.
  • Struckmann, J. R. Clinical efficacy of micronized purified flavonoid fraction: an overview. J Vasc.Res 1999;36 Suppl 1:37-41. View abstract.
  • Uehara, M. [Prevention of osteoporosis by foods and dietary supplements. Hesperidin and bone metabolism]. Clin.Calcium 2006;16(10):1669-1676. View abstract.
  • Yamada, M., Tanabe, F., Arai, N., Mitsuzumi, H., Miwa, Y., Kubota, M., Chaen, H., and Kibata, M. Bioavailability of glucosyl hesperidin in rats. Biosci.Biotechnol.Biochem. 2006;70(6):1386-1394. View abstract.
  • Yamamoto, M., Suzuki, A., Jokura, H., Yamamoto, N., and Hase, T. Glucosyl hesperidin prevents endothelial dysfunction and oxidative stress in spontaneously hypertensive rats. Nutrition 2008;24(5):470-476. View abstract.
  • Yanez, J. A., Remsberg, C. M., Miranda, N. D., Vega-Villa, K. R., Andrews, P. K., and Davies, N. M. Pharmacokinetics of selected chiral flavonoids: hesperetin, naringenin and eriodictyol in rats and their content in fruit juices. Biopharm.Drug Dispos. 2008;29(2):63-82. View abstract.
  • Andersen KE. Hesperidin methyl chalcone?-?a new cosmetic contact allergen. Contact Dermatitis. 2015;72(6):402-4. View abstract.
  • Beltramino R, Penenory A, Buceta AM. An open-label, randomized multicenter study comparing the efficacy and safety of Cyclo 3 Fort versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Angiology 2000;51:535-44.. View abstract.
  • Cappelli R, Nicora M, Di Perri T. Use of extract of Ruscus aculeatus in venous disease in the lower limbs. Drugs Exp Clin Res 1988;14:277-83. View abstract.
  • Cho, YA, Choi, DH, and Choi, JS. Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. J Pharm Pharmacol. 2009;61(6):825-829. View abstract.
  • Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology 1994;45:566-73. View abstract.
  • Craig WJ. Health-promoting properties of common herbs. Am J Clin Nutr 1999;70:491-9. View abstract.
  • Demonty I, Lin Y, Zebregs YE, et al. The citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately hypercholesterolemic men and women. J Nutr. 2010;140(9):1615-20. View abstract.
  • Di Carlo G, Mascolo N, Izzo AA, Capasso F. Flavonoids: Old and new aspects of a class of natural therapeutic drugs. Life Sci 1999;65:337-53. View abstract.
  • Giannini I, Amato A, Basso L, Tricomi N, Marranci M, Pecorella G, Tafuri S, Pennisi D, Altomare DF. Flavonoids mixture (diosmin, troxerutin, hesperidin) in the treatment of acute hemorrhoidal disease: a prospective, randomized, triple-blind, controlled trial. Tech Coloproctol. 2015 Jun;19(6):339-45. View abstract.
  • Guilhou JJ, Dereure O, Marzin L, et al. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology 1997;48:77-85.. View abstract.
  • Ho Y, Tan M, Seow-Choen F. Micronized purified flavonidic fraction compared favorably with rubber band ligation and fiber alone in the management of bleeding hemorrhoids. Dis Colon Rectum 2000;43:66-9. View abstract.
  • Koyuncu H, Berkarda B, Baykut F, et al. Preventive effect of hesperidin against inflammation in CD-1 mouse skin caused by tumor promoter. Anticancer Res 1999;19:3237-41.
  • Martin BR, McCabe GP, McCabe L, et al. Effect of hesperidin with and without a calcium (Calcilock) supplement on bone health in postmenopausal women. J Clin Endocrinol Metab 2016;101(3):923-7. View abstract.
  • Middleton E. Some biological properties of plant flavonoids. Ann Allergy 1988;61:53-7. View abstract.
  • Milenkovic D, Deval C, Dubray C, et al. Hesperidin displays relevant role in the nutrigenomic effect of orange juice on blood leukocytes in human volunteers: a randomized controlled cross-over study. PLoS One 2011;6(11):e26669. View abstract.
  • Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids. Br J Surgery 2000;87:868-72. View abstract.
  • Morand C, Dubray C, Milenkovic D, et al. Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr 2011;93(1):73-80. View abstract.
  • Ohara T, Muroyama K, Yamamoto Y, et al. Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial. Nutr J 2016;15:6. View abstract.
  • Pecking AP, Fevrier B, Wargon C, Pillion G. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology 1997;48:93-8.. View abstract.
  • Piao, YJ and Choi, JS. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats. Arch Pharm Res. 2008;31(4):518-522. View abstract.
  • Rizk, S. M and Sabri, N. A. Evaluation of Clinical Activity and Safety of Dalfon&reg; 500mg in Type 2 Diabetic Femal Patients. Saudi Pharmacetical Journal 3-17-2009;199-209.
  • Rizza S, Muniyappa R, Iantorno M, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab 2011;96(5):E782-92. View abstract.
  • Uesawa, Y. and Mohri, K. Hesperidin in orange juice reduces the absorption of celiprolol in rats. Biopharm Drug Dispos. 2008;29(3):185-188. View abstract.

More Resources for HESPERIDIN

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.